Group No Serum β2-M (mg/L,)
(mean ±SD)
P positive rate (%) P
Controls 1002 0.99±4.47   7.88  

Female benign tumor

141

1.19±2.55

>0.05

20.00

<0.05

Female breast Ca.

201

2.05±4.81

< 0.05

30.84

<0.05

Female breast Ca,

         

ages:

         

<40years

46

2.51±6.64

 

39.13

 

40-60years

127

2.15±4.47

>0.05

28.34

>0.05

60years

19

0.84±1.75

>0.05

7.14

< 0.01

cilinical stages

         

14

1.77±2.48

 

28.57

 

116

2.50±3.61

>0.05

34.48

>0.05

24

2.18±4.15

>0.05

33.33

>0.05

14

0.74±1.85

>0.05

28.57

>0.05

Benign tumor

243

0.68±2.20

>0.05

7.81

>0.05

Thyroid Ca.

95

2.84±4.56

<0.05

34.73

<0.01

Thyroid Ca.:

         

Male:

26

1.71±2.88

 

23.07

 

female:

69

3.26±5.00

>0.05

36.23

>0.05

ages:

         

<40years

31

2.04±4.35

 

22.58

 

40-60years

45

3.66±4.96

>0.05

46.67

<0.05

60years

19

2.17±3.71

>0.05

26.31

>0.05

cilinical stages

         

28

2.07±4.18

 

28.57

 

Ⅱ-     Ⅲ

18

2.15±1.674.95

>0.05

33.33

>0.05

20

0.23±1.35

< 0.01

0

<0.01

Cell  types;          
Follicular- -thyroid adenoma 42 2.07±3.75   19.07  

Papillary-thyroid adenoma

18

2.71±4.25

>0.05

44.44

<0.05

Table 3: Mean levels of serum β2-microglobulin in female breast cancer patients , thyroid cancer patients and benign tumor patients.